Publikationen

Grundlegende Voraussetzung für die flächendeckende Verbesserung der Behandlungskonzepte ist die Publikation der Forschungsergebnisse. iOMEDICO unterstützt die internationalen Richtlinien zu Transparenz und Veröffentlichung von medizinischen Forschungsergebnissen.

Wir präsentieren unsere Daten regelmäßig auf nationalen und internationalen Kongressen. Unsere Publikationen erscheinen in wissenschaftlich renommierten, internationalen Fachzeitschriften. Autoren sind die Studienleiter, Prüfärzte mit besonders hoher Patiententeilnahme und Wissenschaftler von iOMEDICO.

TITEL
STUDIE
JAHR
Clinical research platform into molecular testing, treatment and outcome of non-small cell lung carcinoma patients (CRISP): A prospective German registry in stage IV NSCLC AIO-TRK-0315.

Griesinger, F., Eberhardt, W.E., Marschner, N., Jänicke, M., Spring, L., Sahlmann, J., Karatas, A., Hipper, A., Sebastian, M., Thomas, M., 2016.

J Clin Oncol 34 (suppl; abstr TPS9108). doi: 10.1200/JCO.2016.34.15_suppl.TPS9108

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: ASCO / Journal: Journal of Clinical Oncology
CRISP
2016
A Cross-Sectional Investigation of Fatigue, Mucositis, Hand-Foot Syndrome and Dysgeusia in Advanced Renal Cell Carcinoma Treatment: Final Results From the FAMOUS Study.

Goebell, P.J., Müller, L., Hurtz, H.-J., Koska, M., Busies, S., Marschner, N., 2016.

Clin Genitourin Cancer, 63–68. doi:10.1016/j.clgc.2015.09.004

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: - / Journal: Clinical Genitourinary Cancer
TNK
2016
The PAZOREAL study: A non-interventional study to assess efficacy and safety of Pazopanib and everolimus in a real life settin; reflecting a changing mRCC treatment landscape.

Goebell, P.-J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Welslau, M., 2016.

Oncol Res Treat 39 (suppl.3)(P883), 267. doi:10.1159/000449050

Abstract

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
PAZOREAL
2016
Systemic palliative treatment in patients with metastatic colorectal cancer tested for their (K)RAS mutation status – Real-life data from the clinical Tumour Registry Colorectal Cancer (TKK).

Zahn, M.-O., Schnell, R., Karcher, A., Schnitzler, M., Wetzel, N., Fleitz, A., Marschner, N., 2016.

Oncol Res Treat 39(suppl5)(V171), 42. ddoi:10.1159/000449050

Abstract

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TKK
2016
Time to deterioration as measure for symptom burden and quality of life – Data from the LuLife project in 507 patients with non-small cell lung cancer in Germany.

von Verschuer, U., Sandner, R., Tessen, H.-W., Emde, T.-O., Schnitzler, M., Binninger, A., Jänicke, M., Marschner, N., 2016.

Oncol Res Treat 39 (suppl 3)(V986), 303. doi:10.1159/000449050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLK
2016
Prophylaxis of chemotherapy-induced neutropenia with Lipegfilgrastim in patients with lung cancer: results from an interim analysis of the non-interventional study NADIR.

Potthoff, K., Lück, A., Frost, N., Losem, C., Weide, R., Schulz, H., 2016.

Oncol Res Treat 39 (suppl3)(P949), 292. doi:10.1159/000449050

Abstract

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NADIR
2016
Patient-reported outcomes of 905 patients with breast cancer two years after start of curative systemic treatment.

Marschner, N., Trarbach, T., Dörfel, S., Meyer, D., Müller-Hagen, S., Zaiss, M., Boller, E., Kruggel, L., 2016.

Oncol Res Treat 39 (suppl 5)(V385), 116. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TMK
2016
Overall survival of 4865 patients with metastatic solid tumours treated in German routine practice – combined results from four prospective, multicentre cohort studies.

Marschner, N., Potthoff, K., Schnell, R., Tesch, H., Zahn, M.-O., Hegewisch-Becker, S., Jänicke, M., 2016.

Oncol Res Treat 39 (suppl.3)(V174), 43. doi:10.1159/000449050

Abstract

Indikation: Other, Sonstige / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
Indikationsübergreifend
2016
Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: Final results of the non-interventional study NABUCCO.

Marschner, N., Potthoff, K., Salat, C., Söling, U., Hansen, R., Grebhardt, S., Harde, Nusch, A., 2016.

Oncol Res Treat 39 (suppl3)(P598), 183. doi:10.1159/000449050

Abstract

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
NABUCCO
2016
1st -line treatment of patients with mantle cell lymphoma: Treatment reality and first outcome data from the German prospective TLN Registry.

Knauf, W., Bertram, Fietz, T., Kirste, T., Grugel, R., Schnitzler, Abenhardt, W., 2016.

Oncol Res Treat 39 (suppl 3)(V364), 120. doi:10.1159/000449050

Abstract

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TLN
2016